Evaluation of Physiological Parameters of Intestinal Sulfate-Reducing Bacteria Isolated from Patients Suffering from IBD and Healthy People

Ivan Kushkevych 1,*, Jorge Castro Sangrador 1,2, Dani Dordević 3, Monika Rozechnalová 4, Martin Černý 1, Roman Fafula 3, Monika Viteřová 1 and Simon K.-M. R. Rittmann 5,6

1 Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 753/5, 62500 Brno, Czech Republic; jorgecas@usal.es (J.C.S.); cernyarchaea@mail.muni.cz (M.C.);
vitezova@sci.muni.cz (M.V.)
2 Faculty of Biology, University of Salamanca, Campus Miguel de Unamuno C/Donantes de sangre, s/n 37007 Salamanca, Spain
3 Department of Plant Origin Foodstuffs Hygiene and Technology, Faculty of Veterinary Hygiene and Ecology, University of Veterinary and Pharmaceutical Sciences, 61242 Brno, Czech Republic; dani_dordevic@yahoo.com
4 Centre of Region Hana for Biotechnological an Agricultural Research, Central Laboratories and Research Support, Faculty of Science, Palacky University Olomouc, 77900 Olomouc, Czech Republic; Jarosova.Monika@email.cz
5 Department of Medical Biophysics, Danylo Halytsky Lviv National Medical University, 69 Pekarska St., 79010 Lviv, Ukraine; roman_fafula@ukr.net
6 Archaea Physiology & Biotechnology Group, Department of Functional and Evolutionary Ecology, Universität Wien, Althanstraße 14, 1090 Vienna, Austria; simon.rittmann@univie.ac.at
* Correspondence: kushkevych@mail.muni.cz (I.K.); simon.rittmann@univie.ac.at (S.K.-M.R.R.); Tel.: +420–549–495–315 (I.K.); +431–427–776–513 (S.K.-M.R.R.)

Received: 25 May 2020; Accepted: 16 June 2020; Published: 19 June 2020

Abstract: Background: Inflammatory bowel diseases (IBDs) are multifactorial illnesses of the intestine, to which microorganisms are contributing. Among the contributing microorganisms, sulfate-reducing bacteria (SRB) are suggested to be involved in the process of bowel inflammation due to the production of hydrogen sulfide (H2S) by dissimilatory sulfate reduction. The aims of our research were to physiologically examine SRB in fecal samples of patients with IBD and a control group, their identification, the study of the process of dissimilatory sulfate reduction (sulfate consumption and H2S production) and biomass accumulation. Determination of biogenic elements of the SRB and evaluation of obtained parameters by using statistical methods were also included in the research. The material for the research consisted of 14 fecal samples, which was obtained from patients and control subjects. Methods: Microscopic techniques, microbiological, biochemical, biophysical methods and statistical analysis were included. Results: Colonies of SRB were isolated from all the fecal samples, and subsequently, 35 strains were obtained. Vibrio-shaped cells stained Gram-negative were dominant in all purified studied strains. All strains had a high percentage of similarity by the 16S rRNA gene with deposited sequences in GenBank of Desulfovibrio vulgaris. Cluster analysis of sulfate reduction parameters allowed the grouping of SRB strains. Significant (p < 0.05) differences were not observed between healthy individuals and patients with IBD with regard to sulfate reduction parameters (sulfate consumption, H2S and biomass accumulation). Moreover, we found that manganese and iron contents in the cell extracts are higher among healthy individuals in comparison to unhealthy individuals that have an intestinal bowel disease, especially ulcerative colitis. Conclusions: The observations obtained from studying SRB emphasize differences in the intestinal microbial processes of healthy and unhealthy people.

J. Clin. Med. 2020, 9, 1920; doi:10.3390/jcm9061920 www.mdpi.com/journal/jcm
Keywords: ulcerative colitis; intestinal microbiota; bowel disease; sulfate reduction; hydrogen sulfide; toxicity

1. Introduction

Inflammatory bowel diseases (IBD) are illnesses whose incidence have increased in recent years in European countries [1–4]. IBD include two types of conditions: Crohn’s disease (CD) and ulcerative colitis (UC) [2,3]. The etiology of these diseases remains uncertain, and it is not known how environmental, genetic, microbial, cellular and molecular factors involved cooperate to make IBD happen [5]. A microbiological origin has been suggested, as the illnesses respond to the treatment with antibiotics, but no conclusive evidence has been found [6–10]. Symptomatology of IBD, in general, comprises watery diarrhea with blood, weight loss, abdominal pain, increased gut permeability, an urgency to defecate, arthritic effects and general discomfort [7,11].

Attempts to address a microbial origin to IBD by traditional techniques have failed. The more powerful explanation for the disease in humans is believed to be the genetic predisposition for impairment of the immune response, acting against antigens of the normal microbiota [3,5]. However, research has provided much evidence on the relationship between microorganisms and IBD and the involvement of bacterial sulfate metabolism on them [12–16]. Studies of the intestinal microbiota of UC patients and especially the study with animal models of gut inflammation demonstrate the relevance of sulfate-reducing bacteria (SRB) for the beginning and the prevalence of the process of inflammation [11,17,18].

An increased level of SRB and the final products of their metabolism (hydrogen sulfide (H₂S) and acetate) are always detectable in the feces of patients with IBD [19–27]. SRB use sulfate as an electron acceptor in the process of dissimilatory sulfate reduction (DSR). The final product of this process is H₂S, which can be toxic, mutagenic and cancerogenic [19]. For this process, electron donors such as molecular hydrogen (H₂) [28,29] or a varied range of organic compounds are necessary. Organic compounds (e.g., lactate, pyruvate, ethanol, amino acids, etc.) can be used by SRB as a carbon and energy source [30–32]. These compounds are usually oxidized to acetate, which can be an additional factor involved in IBD development [7,9,33].

The dominant species of SRB in the human intestine belong to Desulfovibrio sp. [7,12,34,35]. The studies emphasize connections between the presence of SRB in the intestines and the prevalence of ailments, such as cholecystitis, brain abscesses and abdominal cavity ulcerative enterocolitis [7,11,36,37]. SRB are not the only organisms of the intestine producing H₂S. Although SRB isolates coming from the intestine of humans have been reported to belong almost exclusively to Desulfovibrio sp., other genera are also part of the SRB microbiota: Desulfotomaculum, Desulfobulbus, Desulfomicrobium, Desulfomonas, Desulfonema [12,28]. In the intestine, SRB, mainly Desulfovibrio sp., form biofilms together with other intestinal bacteria, such as species of Bacteroides, Pseudomonas, Clostridium and Escherichia. Desulfovibrio spp. are also present in a certain percentage of the healthy population [38–40]. They were first isolated from human feces in 1976 by W.E.C. Moore and identified as Desulfomonas pigra [41], which was then reclassified as Desulfovibrio piger [34]. Desulfovibrio belongs to Desulfovibrionaceae [42]. SRB are present in various environments and they make a high impact on animal and human health since their presence is a possible contributing factor in the development of inflammatory bowel diseases [20].

The aim of the research was to detect SRB in fecal samples of patients with IBD and healthy people, to purify these cultures and to identify them (phylogenetically by 16S rRNA gene), to compare their morphology and to construct a phylogenetic tree based on the obtained sequences as well as to study the process of dissimilatory sulfate reduction (sulfate consumption and H₂S production) and biomass accumulation. Determination of important trace elements for their metabolism and evaluation of obtained parameters by using statistical methods will as well be sought in this research.
2. Experimental Section

The fecal samples from healthy people (4 samples) and patients with IBD (10 samples) were collected. A summary of the features of the patients and healthy subjects used in this study is presented in Tables 1 and 2. All the bacterial strains, which were isolated in the frame of this study, were purified. Fecal samples of 10 patients with IBD were treated in the University Hospital of Ostrava (Czech Republic) and 4 fecal samples of healthy subjects were collected in the same institution. The latter was used in the present study as the controls. All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of University Hospital Ostrava and Masaryk University (551/2018). All bacterial strains were kept in the collection of microorganisms in the Laboratory of Anaerobic Microorganisms of the Department of Experimental Biology at Masaryk University (Brno, Czech Republic).

Table 1. Patients and control subject’s characteristics.

| Sample Name | Sex   | Diagnosis | Age | Weight (kg) | Year of Diagnosis | State of the Disease*          |
|-------------|-------|-----------|-----|-------------|--------------------|-------------------------------|
| M-01        | Female | CD        | 21  | 57          | 2011               | Short-term remission          |
| M-02        | Male   | CD        | 34  | 104         | 2013               | Short-term remission          |
| M-03        | Female | UC        | 66  | 78          | 2012               | Short-term remission          |
| M-04        | Female | UC        | 41  | 53          | 2005               | Disease flare                 |
| M-05        | Male   | UC        | 35  | 92          | 2018               | Short-term remission          |
| M-06        | Female | UC        | 39  | 120         | 2013               | Disease flare                 |
| M-07        | Male   | UC        | 44  | 61          | 2014               | Long-term remission           |
| M-08        | Female | UC        | 20  | 70          | 2003               | Short-term remission          |
| M-09        | Male   | CD        | 24  | 73          | 2006               | Long-term remission           |
| M-10        | Male   | CD        | 34  | 70          | 2018               | Disease flare                 |
| Z-8         | Male   | Control   | 46  | 108         | –                  | Healthy                       |
| Z-9         | Male   | Control   | 53  | 72          | –                  | Healthy                       |
| Z-11        | Male   | Control   | 42  | 95          | –                  | Healthy                       |
| Z-12        | Male   | Control   | 26  | 78          | –                  | Healthy                       |

* The induction of remission is dated from for each sample as followed: 5/2019 (M-01), 10/2019 (M-02), 4/2019 (M-03), 10/2019 (M-05), 2/2015 (M-07), 7/2019 (M-08), 11/2017 (M-09).

All donors who were suffering from IBD at the given time were undergoing therapy (with exception of a donor of sample M-02). Prescribed therapeutics which served for attenuation and management of the disease are summarized in Table 2.

Table 2. Prescribed and taken therapeutics assigned to IBD sample donors*.

| Sample name | Azathioprine | Mesalazine | Glucocorticoids | Biological Treatment | Omeprazole |
|-------------|--------------|------------|-----------------|----------------------|------------|
| M-01        | Imuran 50 mg  | –          | –               | –                    | –          |
| M-02        | –            | Pentasa 500 mg | –              | –                    | –          |
| M-03        | –            | Pentasa 1 g | Cortiment 9 mg  | –                    | Helic 10 mg|
| M-04        | Imuran 50 mg  | Pentasa 1 g | Prednison 5 mg  | –                    | –          |
| M-05        | –            | Pentasa 1 g | Cortiment 9 mg  | –                    | –          |
| M-06        | –            | Asacol 400 mg | Cortiment 9 mg | Entivio 300 mg       | –          |
| M-07        | –            | Pentasa 1 g | –               | –                    | –          |
| M-08        | Imasup 50 mg  | Salofalk 3 g | –               | Remsima 400 mg       | –          |
2.1. Bacterial Culture Isolation, Purification and Cultivation

Intestinal SRB strains were grown in the SRB medium modified by Kováč and Kushkevych (2016) [43] based on the cultivation of Postgate medium for SRB [35]. Ascorbic acid solution (10% (w/v)) was prepared and added into the medium to a final concentration of 0.1 g L⁻¹. Ascorbic acid is an important compound for decreasing the redox potential (E₀ = −100 mV). For the detection of growing colonies, a 10% (w/v) of Mohr’s salt solution (NH₄)₂Fe(SO₄) × 6H₂O was added to a final concentration of 10 mL solution per L of the medium. Iron ions included in Mohr’s salt react with H₂S produced by SRB cultures forming a black precipitate (FeS), which allows visualizing the SRB colonies. After completion, the pH of the medium was adjusted to approximately 7.5 with a 1 mol L⁻¹ NaOH solution. For the cultivation in Petri plates, the same composition of medium was used, with the addition of nutrient agar in a concentration of 20 g L⁻¹ before the sterilization. For obtaining pure SRB cultures, isolation and purification procedure was carried out. The present experiment was started from the SRB fecal samples from the described in Table 1 subjects.

Positive samples containing SRB were diluted in a series of tube tests containing modified SRB liquid medium. The isolated colonies were suspended in an Eppendorf containing modified SRB liquid medium. The newly isolated and suspended colonies were cultivated at 37 °C, and after 5 d, precipitation of blacked ferrous sulfide indicated the proper growth of SRB. This whole process was repeated 3–5 times to assure a complete purification of SRB from other satellite microorganisms.

The purification process was systematically monitored with the light microscope by the Gram staining of the isolated colonies after the sequential steps of isolation.

2.2. DNA Isolation, 16S rDNA Amplification and Sequence Analysis

Isolation of the bacterial DNA was a procedure that shall only be carried out when the isolated colonies have passed the purification process so that the extracted DNA was uniformed. A simple technique was used with the samples concerning this study: liquid cultures have a total volume of 1 mL. Firstly, for every purified sample that has undergone cultivation for three days, 200 μL were separated into Eppendorf tubes and centrifuged at 13,000×g to discard the supernatant. Then, biomass was suspended in 50 μL of sterile deionized water.

The resuspended colonies were disrupted by heating at 98 °C for three min in an Eppendorf block heater. Afterwards, the samples with the disrupted cells were centrifuged at 13,000×g for 3 min. After this procedure, the supernatant remaining after the centrifugation step already contains the DNA of interest. The unequivocal identification of the cultivated strains was obtained by the 16S rDNA sequencing technique. For the amplification of the fragment of interest, 2 μL of the DNA extract of each sample was put together in a 300 μL Eppendorf with 1 μL of Taq PCR Master Mix Kit (Cat. No. 201445) and 0.1 μL each of a pair of universal primers: forward primer 8FL 100 μmol L⁻¹ (5'-AGT-AGC-CTG-GCT-GCA-CG3') and reverse primer 806R 100 mol L⁻¹ (5'-GGG-ATC-CCA-GAG-TAT-CAA-T3') [44,45].

PCR was carried out in a Schoeller PCR Thermocycler with a gradient (Labcyler Gradient), applying the program with 35 cycles. To check the outcome of the PCR, all reaction products were put through electrophoresis in 1.5% (w/v) agarose gel. Preparation of one of the said gels requires the mix of 75 mL or TAE (Tris-acetate-EDTA) or TBA (Tri-borate-EDTA) buffer with 1 g of agarose. The mixture is boiled up in a microwave until the whole solution acquires transparency. After boiling, and advisable a few minutes of cooling down later, Gelred® Nucleic Acid Gel Stain was added in a proportion of 1 μL of dye per mL of the gel prepared. 3 μL of each PCR product was mixed with approximately and an equal volume of a 6× DNA loading dye and loaded into a well. Electrophoresis was run for 1 h at a tension of 80 V.
The purification of the PCR products was conducted via FastGene® Gel/PCR Extraction Kit Cat. No. FG-91202. PCR products were afterwards sent to sequence analysis of the 16S rRNA gene fragment amplified. The obtained results of sequences were launched in BLAST, compared with already existing sequences of SRB and eventually uploaded in GenBank under the following accession numbers: MT027899, MT093800, MT093826, MT093820, MT093819, MT093823, MT093825, MT093830, MT093829, MT093831.

2.3. Measurement of Sulfate Consumption

The sulfate concentration in the liquid medium was measured by the turbidimetric method after time intervals of the cultivation. In total, 40 mg L⁻¹ BaCl₂ solution was prepared in 0.12 mol L⁻¹ HCl and mixed with glycerol in a 1:1 ratio. The supernatant of the sample was obtained by centrifugation at 5000×g at 23 °C and 1 mL was added to 10 mL of BaCl₂ : glycerol solution and carefully mixed as described before [46]. The absorbance of the mixed solution was measured after 10 min at 520 nm (Spectrasonic Genesis 5, Ecublens, Switzerland). A cultivation medium without bacteria growth was used as a control.

2.4. Measurement of Hydrogen Sulfide Production

Measurement of the H₂S produced in every sample was performed using the methylene blue method [47]. According to this procedure, 1 mL of cell-free culture medium of each centrifuged sample was pipetted into 10 mL of an aqueous solution of 5 g L⁻¹ zinc acetate. Two milliliters of a solution of 0.75 g L⁻¹ of p-amino dimethylaniline in 2 mol L⁻¹ sulfuric solution was added, and the solutions were standing for 5 min at room temperature. Thereafter, 0.5 mL of 12 g L⁻¹ ferric chloride solution in 15 mmol L⁻¹ sulfuric acid solution was added, and the final mixture was standing for another 5 min and was centrifuged at 5000×g at 23 °C for 10 min. Parallel, the procedure was repeated with the initial addition of distilled water to have a control tube. After the procedure, the absorbance of the samples was measured at a wavelength of 665 nm [47].

2.5. Determination of Biomass Concentration

In total, 1 mL of liquid medium without Mohr's salt in a plastic cuvette was measured in a biophotometer (Eppendorf BioPhotometer®D30, Hamburg, Germany) as a blank. The same procedure with the bacterial suspension was performed. The optical density (OD₅₆₅) was always measured before the experiments to provide approximately the same amount of SRB [27].

2.6. Statistical Analysis

Statistical calculations of the results were carried out using the MS Office (2010), Origin 8.0 (https://www.originlab.com/) and Statistica 13 (http://www.statsoft.com/) software programs. Using the experimental data, the basic statistical parameters (mean: M, standard error: m, M ± SE) were calculated. The accurate approximation was when \( P \leq 0.05 \) [48].

Hierarchical cluster analysis was applied to experimental data of measured variables by Ward’s method with Statistica software version 13.5.0.17, in order to classify experimental strains into groups of similar subjects. The cluster analyses were conducted by the inclusion of the following parameters: sulfate consumption, H₂S production, biomass accumulation, and all parameters together as well as concentration data of physiological important elements (Na⁺, K⁺, Ca²⁺, Fe²⁺, Cu²⁺, Mg²⁺, Mn²⁺ separately and all described elements together). Cluster analysis gave overall differences among compared groups. Statistically significant differences between strains coming from healthy and unhealthy people were sought by one-way ANOVA for those variables that distribute normally, while a nonparametric test (Mann–Whitney U test) was performed for non-normally distributed variables. Both tests were conducted with IBM SPSS Statistics package, version 23. A \( p \)-value of less than 0.05 was considered significant.
3. Results

3.1. Microscopic Analysis of the Cultures

From the 14 fecal samples originally studied, 35 strains were isolated and purified. Out of these 35 strains, 24 were obtained from patients with IBD and the remaining 11 were purified from healthy subjects. Morphological analysis was performed on SRB isolates from both groups, showing that no differences were found in cellular shape. Vibrio-shaped cells stained Gram-negative were present in all purified strains (Figure 1).

![Figure 1](image1.png)

Figure 1. Morphological distributions of sulfate-reducing bacteria (SRB) mixed cultures from healthy people (A) and patients with inflammatory bowel diseases (IBDs, B; magnification × 1000).

3.2. Sequence Analysis

Sequence analysis of 16S rDNA allowed the unequivocal identification of the strains. All sequences of the studied strains were compared with SRB species uploaded in NCBI and identified as Desulfovibrio vulgaris. Accession number, amplicon lengths and similarities with reference strains of Desulfovibrio genus are presented in Table 3. Obtained sequences of the 16S rRNA gene from strains isolated from healthy and not healthy persons were compared with existing sequences of intestinal SRB from GenBank by Multiple Sequence Alignment (MSA) and a phylogenetic tree was constructed (Figure 2). Isolated and purified strains belong to one cluster in which they are grouped with Desulfovibrio longreachensis ACM 3958 and Desulfovibrio vulgaris subsp. Oxamicus DSM 1925. Other intestinal SRB species were grouped in more distant clusters.

![Figure 2](image2.png)

Figure 2. Phylogenetic tree based on sequences analysis of the 16S rRNA gene known and studied intestinal SRB strains (built by the neighbor-joining method).
Table 3. Identified species of pure bacterial cultures by sequence analysis of the 16S rRNA gene.

| Identified Bacteria and Accession in GenBank | Amplicon Length (bp) | % Identity | Reference Strains of Desulfovibrio Genus | Reference Accession in GenBank |
|--------------------------------------------|----------------------|------------|-----------------------------------------|--------------------------------|
| Desulfovibrio vulgaris M6_1 MT027815       | 745                  | 99.06      | D. vulgaris DSM 644                      | NR_112657.1                   |
|                                           |                      |            | D. vulgaris RCH1                         | CP002297.1                    |
|                                           |                      |            | D. vulgaris DP4                          | CP000527.1                    |
| Desulfovibrio vulgaris M6_2 MT027923       | 740                  | 98.65      | D. vulgaris RCH1                         | CP002297.1                    |
|                                           |                      |            | D. vulgaris DSM 644                      | NR_112657.1                   |
|                                           |                      |            | D. vulgaris DP4                          | CP000527.1                    |
| Desulfovibrio vulgaris M6_3 MT027925       | 740                  | 98.65      | D. vulgaris RCH1                         | CP002297.1                    |
|                                           |                      |            | D. vulgaris DSM 644                      | NR_112657.1                   |
|                                           |                      |            | D. vulgaris DP4                          | CP000527.1                    |
| Desulfovibrio vulgaris M1_1 MT027899       | 740                  | 98.65      | D. vulgaris RCH1                         | CP002297.1                    |
|                                           |                      |            | D. vulgaris DSM 644                      | NR_112657.1                   |
|                                           |                      |            | D. vulgaris DP4                          | CP000527.1                    |
| Desulfovibrio vulgaris M1_2 MT027900       | 740                  | 98.65      | D. vulgaris RCH1                         | CP002297.1                    |
|                                           |                      |            | D. vulgaris DSM 644                      | NR_112657.1                   |
|                                           |                      |            | D. vulgaris DP4                          | CP000527.1                    |
| Desulfovibrio vulgaris M3_1 MT093732       | 740                  | 98.65      | D. vulgaris RCH1                         | CP002297.1                    |
|                                           |                      |            | D. vulgaris DSM 644                      | NR_112657.1                   |
|                                           |                      |            | D. vulgaris DP4                          | CP000527.1                    |
| Desulfovibrio vulgaris M3_2 MT093731       | 740                  | 98.65      | D. vulgaris RCH1                         | CP002297.1                    |
|                                           |                      |            | D. vulgaris DSM 644                      | NR_112657.1                   |
|                                           |                      |            | D. vulgaris DP4                          | CP000527.1                    |
| Desulfovibrio vulgaris M4_3 MT093736       | 740                  | 98.65      | D. vulgaris RCH1                         | CP002297.1                    |
|                                           |                      |            | D. vulgaris DSM 644                      | NR_112657.1                   |
|                                           |                      |            | D. vulgaris DP4                          | CP000527.1                    |
| Desulfovibrio vulgaris M5_1 MT093737       | 740                  | 98.65      | D. vulgaris RCH1                         | CP002297.1                    |
|                                           |                      |            | D. vulgaris DSM 644                      | NR_112657.1                   |
|                                           |                      |            | D. vulgaris DP4                          | CP000527.1                    |
| Desulfovibrio vulgaris M5_2 MT093788       | 740                  | 98.65      | D. vulgaris RCH1                         | CP002297.1                    |
|                                           |                      |            | D. vulgaris DSM 644                      | NR_112657.1                   |
|                                           |                      |            | D. vulgaris DP4                          | CP000527.1                    |
| Desulfovibrio vulgaris M7_1 MT093774       | 740                  | 98.65      | D. vulgaris RCH1                         | CP002297.1                    |
|                                           |                      |            | D. vulgaris DSM 644                      | NR_112657.1                   |
|                                           |                      |            | D. vulgaris DP4                          | CP000527.1                    |
| Strain Name | Accession Number | Identity | Reference | Genus and Species |
|-------------|------------------|----------|-----------|-------------------|
| Desulfovibrio vulgaris M7_2 MT093772 | | 762 | 99.47 | D. vulgaris RCH1, D. vulgaris DSM 644, D. vulgaris Hildenborough |
| Desulfovibrio vulgaris M7_3 MT093800 | | 766 | 99.61 | D. vulgaris DP4, D. vulgaris RCH1, D. vulgaris DSM 644 |
| Desulfovibrio vulgaris M8 MT093799 | | 762 | 99.34 | D. vulgaris RCH1, D. vulgaris DSM 644, D. vulgaris DP4 |
| Desulfovibrio vulgaris M9_1 MT093798 | | 768 | 99.60 | D. vulgaris RCH1, D. vulgaris DSM 644, D. vulgaris DP4 |
| Desulfovibrio vulgaris M9_2 MT093820 | | 315 | 98.10 | D. vulgaris PhM31, D. vulgaris PhM22 |
| Desulfovibrio vulgaris M9_3 MT093819 | | 764 | 99.73 | D. vulgaris RCH1, D. vulgaris DSM 644, D. vulgaris DP4 |
| Desulfovibrio vulgaris M10_1 MT093826 | | 770 | 99.09 | D. vulgaris RCH1, D. vulgaris DSM 644, D. vulgaris DP4 |
| Desulfovibrio vulgaris M9_3 MT093825 | | 629 | 99.05 | D. vulgaris RCH1, D. vulgaris DSM 644, D. vulgaris DP4 |
| Desulfovibrio vulgaris Z9_3 MT093830 | | 448 | 99.33 | D. vulgaris RCH1, D. vulgaris DSM 644, D. vulgaris DP4 |
| Desulfovibrio vulgaris Z11_1 MT093829 | | 751 | 99.46 | D. vulgaris DP4, D. vulgaris RCH1 |
| Desulfovibrio vulgaris Z12_1 MT093831 | | 463 | 99.13 | D. vulgaris Hildenborough, D. vulgaris RCH1, D. vulgaris DSM 644 |
3.3. Sulfate Consumption, H2S Production and Biomass Accumulation

Ten bacterial strains from healthy and unhealthy persons were compared by the parameters sulfate consumption, H2S production and biomass accumulation (Figure 3). The highest sulfate consumption was observed in all bacterial strains after 24–48 h. The highest rate of this consumption was detected for SRB Strain 1, Strain 2 and Strain 7 (83–90%, 84–89%, 85–91%, respectively). The lower level of sulfate consumption within the first 24 h was observed for Strain 4, Strain 5, Strain 9 and others. In this case, the slowest sulfate consumption (56%) was detected in Strain 4. It should be noted that the sulfate level was stable and almost constant in the medium of all strains after 48 h of cultivation, regardless of their provenience.

![Sulfate Consumption](image1)

![Hydrogen sulfide](image2)

![Biomass Accumulation](image3)

**Figure 3.** Sulfate consumption, H2S production and biomass accumulation by collected stains of SRB during 5, 24 and 48 h (IBD: 1—M1.1, 2—M7.3, 3—M8, 4—M9.2, 5—M9.3; healthy: 6—Z8.2, 7—Z9.2, 8—Z9.3, 9—Z11.1, 10—Z12.1).

The other important parameter is the production of H2S converted from sulfate in the process of DSR. A peak of its production was detected at 24 h of cultivation for every strain. The highest production of H2S was observed for the following bacterial strains: Strain 4 (35 μmol g⁻¹), Strain 5 (40 μmol g⁻¹), Strain 6 (37 μmol g⁻¹). Due to its toxicity at higher concentrations, production of H2S was halted when the highest peak was reached, while biomass continued to increase. The relation of H2S production per gram of biomass is consequently minor at 48 h of cultivation for each strain.
The differences in biomass accumulation were not found to be statistically significant between strains coming from healthy and unhealthy individuals. The highest accumulation of biomass was observed for Strain 7 (fivefold increase at 48 h compared with initial concentration after 5 h of cultivation). The metabolisms’ balance during the initial 24 h of bacterial cultivation was examined. Some percentage of the consumed sulfate was utterly metabolized and was used in the production of H2S while the rest was temporarily stored in the form of the metabolic intermediates: APS and SO3²⁻ (Figure 4).

Figure 4. Balance of sulfate consumption, H₂S production and APS/sulfite accumulation by collected stains of SRB within the first 24 h.

The left scale indicates the percentage of sulfate consumed with respect to the initial concentration of the inorganic compound in the cultivation media, showing that less than 50% of it was consumed within the first 24 h. Thus, the majority of it remained free in the medium.

3.4. Statistical and Cluster Analysis of Sulfate Reduction Parameters and Trace Elements

Sulfate reduction parameters and biomass accumulation (during 48 h) of intestinal SRB strains among healthy individuals and patients with IBDs are shown in Table 4. Statistically significant (p < 0.05) differences in the abovementioned parameters were not found between healthy and unhealthy individuals. All measured parameters (sulfate, H₂S and biomass) after 5 h had statistically significant (p < 0.05) different values in comparison with values measured after 24 and 48 h, both among healthy individuals and patients with IBD.

Table 4. Statistical analysis of sulfate reduction parameters and biomass accumulation of intestinal SRB strains.

| Parameters | Healthy People | Patients with IBD |
|------------|----------------|-------------------|
|            | 5 h            | 24 h              | 48 h              | 5 h            | 24 h            | 48 h            |
| Sulfate    | 23.23 ± 5.85   | 5.61 ± 0.99       | 3.05 ± 0.32       | 25.03 ± 5.34   | 6.26 ± 1.72     | 3.10 ± 0.33     |
| H₂S        | 1.62 ± 0.38    | 30.58 ± 3.63      | 24.48 ± 2.15      | 2.38 ± 1.47    | 32.14 ± 5.47    | 25.58 ± 1.42    |
| Biomass    | 4.35 ± 1.07    | 12.11 ± 1.35      | 15.04 ± 1.37      | 4.02 ± 1.17    | 11.55 ± 1.96    | 14.32 ± 0.82    |

* different letters (a, b, c, d) indicated statistically significant (p < 0.05) difference.

Multivariate analysis of the results obtained from sulfate consumption, H₂S production and biomass accumulation were performed. Cluster analysis is conducted regarding each of these
variables separately and combined (Figure 5); with the aim of sorting the different isolated strains into groups according to the measured variables.

Clusters built from sulfate consumption and biomass accumulation data show that strains were clustered in the three main groups in both cases, apparently regardless of their origin (unhealthy or control subject). Rapid biomass accumulation has been observed for every strain, as was illustrated in Figure 3, notwithstanding, strains that yielded a less accumulation of biomass (D. vulgaris M9.2, D. vulgaris Z9.3, and D. vulgaris Z11.1) form one of the three main groups mentioned. Nevertheless, clusters obtained from H2S production data drop interesting results. Four of the strains obtained from subjects with IBD cluster together in two different clusters, while the remaining strain from an unhealthy person, D. vulgaris M9.3 cluster together with the D. vulgaris Z8.2 strain, both strains represented the highest producers, closely followed by D. vulgaris M8 and D. vulgaris M9.2. Strain D. vulgaris Z8.2 was an H2S overproducer strain coming from a healthy subject, who might be potentially more susceptible to IBD than the other control subjects due to the presented results.

Data obtained regarding intracellular trace element concentration present in the 35 strains isolated were used for cluster analysis. The consistency of the results relies on the fact that measurements were taken with six repetitions per strain.

Analysis based on iron concentration shown in Figure 6 drops the formation of two clusters, first of each is mostly conformed by strains isolated from patients with IBD. Precisely, the first subcluster of this group includes 15 of these strains and just one strain was originating from a healthy subject. Results for Na⁺ and K⁺ showed two clusters, and the ones for calcium formed three clusters. All of them show a more equal proportion of both types of strains, bearing in mind that there is a considerably higher number of strains isolated from unhealthy patients.
For copper, the first subcluster was observed for those strains that do not have a detectable concentration of the element (five from patients and two from healthy subjects). Remaining strains equally distributed in the other subclusters, as it happens with Mg$^{2+}$, finding two main clusters for both elements (Figure 7). Clusters based on Mn$^{2+}$ show that most strains coming from healthy people tend to form subclusters. When combining the cluster analysis of all elements, a similar
outcome was observed, in which the majority of strains from healthy individuals are grouped together (7 out of 11).

Figure 7. Cluster analysis based on concentrations data of physiological important elements (Cu2+, Mg2+, Mn2+ and all described elements in the previous and present figures).

To determine the existence of statistically significant differences between the group of strains coming from patients with IBD (Group 1) and the ones coming from healthy subjects (Group 2),
inferential statistical analysis was carried out. To compare each variable between the two groups of interest, Mann–Whitney U test was applied. The null hypothesis for the test is that the distribution of the element is the same across the groups established. The null hypothesis was rejected for the concentrations of manganese and iron. The concentration of manganese was found to be significantly ($p < 0.05$) higher in the group of strains coming from healthy subjects: $U = 2.619$, $p = 0.008$. The concentration of iron is significantly higher in this group as well: $U = 3.518$, $p = 1.898\cdot10^{-4}$.

4. Discussion

The daily diet can contain a higher amount of H$_2$S if certain food commodities are included in it (sulfur oxides, sulfate polysaccharides (mucin), chondroitin sulfate, carrageenan, etc.). The calculated sulfate in the western dies is over 16.6 mmol sulfate d$^{-1}$ [49], while there is a higher chance (around 50%) that the feces of healthy individuals contain SRB (Desulfovibrio: up to 92%) [12,26]. It should be emphasized that higher H$_2$S concentrations are toxic also for its producer. The growth of Desulfovibrio is stopped in the presence of H$_2$S concentrations higher than 6 mmol L$^{-1}$, though metabolic activity is not 100% inhibited. Lag phase and generation time at H$_2$S concentrations of 5 mmol L$^{-1}$ were two and eight times longer, respectively [8]. Clostridia can also produce H$_2$S, though in smaller quantities [29]. Earlier studies with mice (specially conditioned animals for the experiment) showed 1.14 times higher H$_2$S production among the samples of mice with UC in comparison with healthy animals [20,26].

Sulfate consumption, H$_2$S production, lactate consumption and acetate accumulation play an important role in the environment, concerning the development of the intestinal bowel diseases [17,35,50,51]. Desulfovibrio spp. are related to the occurrence and development of the IBD since it can be very often found in the intestines and feces of people and animals with this ailment. SRB use sulfate as a terminal electron acceptor [21,50,51]. These facts can lead us to the conclusion that sulfate present in different food commodities (some bread, soy flour, dried fruits, brassicas and sausages, as well as some beers, ciders and wines) [49] could be an important factor in the development of bowel disease.

Principal component analysis grouped Desulfovibrio strains from individuals with colitis in one cluster according to the biomass accumulation and H$_2$S production. The other cluster, with the same parameters, was formed from the strains found in healthy individuals. Between sulfate and lactate consumption was found a negative correlation (Pearson correlations, $p < 0.01$). Lower linear regression ($R^2$) was found between biomass accumulation and H$_2$S. Biomass accumulation and H$_2$S production represent kinetic parameters and they play an important role in bowel inflammation, the same as in the development of ulcerative colitis. There is a probable synergy interaction between H$_2$S and acetate produced by SRB since minor factors in the development of bowel disease are sulfate consumption and lactate oxidation [33]. A meta-analysis study showed higher SRB occurrence in patients with UC, showing that the production of H$_2$S reaches toxic levels in IBD individuals, including UC [39].

The higher presence of electron acceptors and donor concentrations resulted in more intense growth of D. piper Vib-7. In this case, the accumulation of H$_2$S and acetate was intense, too. These conditions lead to the occurrence of UC and consequently to bowel cancer. Adverse effects of H$_2$S were noticed on the intestinal mucosa, epithelial cells, the growth of colonocytes [11,17,19–24]. H$_2$S causes phagocytosis and the death of intestinal bacteria [11,19], the same as it induces hyperproliferation and epithelial cell metabolic abnormalities [19]. The colon inflammation is also connected with the presence of SRB and high levels of their metabolites [7,11,13]. The integrity of colonocytes is regulated by H$_2$S concentrations [52,53]. In the samples collected from the people with UC, H$_2$S production is higher [39]. The differences between samples from healthy and unhealthy individuals were noticed in our previous studies too [33]. SRB play an important role in bowel disease development, although the intestinal microbiota represents a complex system, where interactions are occurring between clostridia, methanogens, lactic acid bacteria, etc. [10,29,31,50].
On the other side, many intestinal microorganisms, including lactic acid bacteria and methanogens, can be inhibited by H$_2$S [10,50].

Studies dealing with SRB presence in the intestines and correlation about the prevalence of intestinal bowel disease and H$_2$S are very important since H$_2$S-releasing agents can be seen as promising therapeutic agents [52]. H$_2$S is also confirmed to be an important cardiovascular and nervous system signaling factor. By the conversion to thiosulfate cecal mucosa protects itself from H$_2$S toxic effects [52–54].

5. Conclusions

SRB were present in the samples of healthy and unhealthy individuals. Mainly Desulfovibrio vulgaris was identified by sequence homology analysis of the 16S rRNA gene. It has to be emphasized that differences in cellular shape were not detected among SRB isolates, from both groups (healthy and unhealthy individuals). Isolated and purified strains formed one cluster Desulfovibrio longreachensis ACM 3958 and Desulfovibrio vulgaris subsp. Oxamicus DSM 1925. More distant clusters were grouped with other intestinal SRB species. Statistically significant differences were not found in biomass accumulation between samples obtained from healthy and unhealthy individuals. Biomass accumulated the most for Strain 7 (fivefold increase). Oppositely, statistically significant ($p < 0.05$) differences were observed among all measured parameters (sulfate, H$_2$S and biomass), after 24 and 48 h of cultivation among healthy individuals and patients with IBD. The strains isolated from healthy people grouped mainly the lower clusters (clusters based on manganese). The main elements that distinguished samples, according to the detected trace element, were manganese and iron. These elements were found in higher concentrations among healthy individuals. Our study allows drawing a clearer picture about the microbial processes, which occur during IBD. The physiological differences among SRB strains of healthy and unhealthy individuals are emphasizing the importance of better understanding of microbiological processes involved in IBD. The study has revealed a clearer role of SRB by the combination of physiological, molecular biological and statistical analyses, and specific SRB ecotypes in the development of the intestinal bowel diseases.

Author Contributions: Conceptualization, I.K., J.C.S. and M.V.; methodology, J.C.S., I.K., M.Č. and M.R.; validation, I.K., M.V. and D.D.; formal analysis, S.K.-M.R.R., M.V. and R.F.; investigation, J.C.S., I.K., M.Č. and M.R.; resources, I.K.; data curation, M.V. and I.K.; writing original draft preparation, I.K., J.C.S., D.D., M.V. and S.K.-M.R.R.; writing review and editing, I.K., D.D., J.C.S., and S.K.-M.R.R.; visualization, I.K.; supervision, M.V.; project administration, I.K.; funding acquisition, S.K.-M.R.R., M.V., D.D. and I.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by Grant Agency of Masaryk University (MUNI/A/0947/2019).

Acknowledgments: Open access funding by the University of Vienna.

Conflicts of Interest: The authors declare no conflicts of interest.

References
1. Katz, J.A.; Itoh, J.; Fiocchi, C. Pathogenesis of inflammatory bowel disease. Curr. Opin. Gastroenterol. 1999, 15, 291.
2. Danese, S.; De La Motte, C.; Fiocchi, C. Platelets in inflammatory bowel disease: Clinical, pathogenic, and therapeutic implications. Am. J. Gastroenterol. 2004, 99, 938–945.
3. Danese, S.; Fiocchi, C. Etiopathogenesis of inflammatory bowel diseases. World J. Gastroenterol. 2006, 12, 4807.
4. Scaldaferri, F.; Fiocchi, C. Inflammatory bowel disease: Progress and current concepts of etiopathogenesis. J. Dig. Dis. 2007, 8, 171–178.
5. Fiocchi, C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998, 115, 182–205.
6. Louhinoux, J.; Bronowicz, J.P.; Pereira, I.A. Sulphate-reducing bacteria in human feces and their association with inflammatory diseases. FEMS Microbiol. Ecol. 2002, 40, 107–112.
7. Rowan, F.E.; Docherty, N.G.; Coffey, J.C.; O’Connell, P.R. Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis. Br. J. Surg. 2009, 96, 151–158.

8. Kushkevych, I.; Dördević, D.; Vitěžová, M. Toxicity of hydrogen sulfide toward sulfate-reducing bacteria Desulfovibrio piger Vib-7. Arch. Microbiol. 2019, 201, 389–397.

9. Kushkevych, I.; Dördević, D.; Kollar, P.; Vitěžová, M.; Drago, L. Hydrogen Sulfide as a Toxic Product in the Small–Large Intestine Axis and its Role in IBD Development. J. Clin. Med. 2019, 8, 1054.

10. Kushkevych, I.; Kotrová, V.; Dördević, D.; Buňková, L.; Vitěžová, M.; Amedei, A. Hydrogen Sulfide Effects on the Survival of Lactobacilli with Emphasis on the Development of Inflammatory Bowel Diseases. Biomolecules 2019, 9, 752.

11. Cummings, J.H.; Macfarlane, G.T.; Macfarlane, S. Intestinal Bacteria and Ulcerative Colitis. Curr. Issues Intest. Microbiol. 2003, 4, 9–20.

12. Gibson, G.R.; Cummings, J.H.; Macfarlane, G.T. Growth and activities of sulphate-reducing bacteria in gut contents of health subjects and patients with ulcerative colitis. FEMS Microbiol. Ecol. 1991, 86, 103–112.

13. Coutinho, C.M.I.M.; Coutinho-Silva, R.; Zinkevich, V.; Pearce, C.B.; Ojcius, D.M.; Beech, I. Sulphate-reducing bacteria from ulcerative colitis patients induce apoptosis of gastrointestinal epithelial cells. Microb. Pathog. 2017, 112, 126–134.

14. Kushkevych, I.; Vitěžová, M.; Kos, J.; Kollár, P.; Jampilek, J. Effect of selected 8-hydroxyquinoline-2-carboxanilides on viability and sulfate metabolism of Desulfovibrio piger. J. Appl. Biomed. 2018, 16, 241–246.

15. Kushkevych, I.; Kollar, P.; Suchý, P.; Parak, T.; Pauk, K.; Imramovský, A. Activity of selected salicylamides against intestinal sulfate-reducing bacteria. Neuro Endocrinol. Lett. 2015, 36, 106–113.

16. Kushkevych, I.V. Kinetic Properties of Pyruvate Ferredoxin Oxidoreductase of Intestinal Sulfate-Reducing Bacteria Desulfovibrio piger Vib-7 and Desulfolmicribium sp. Rod-9. Pol. J. Microbiol. 2015, 64, 107–114.

17. Barton, L.L.; Hamilton, W.A. Sulphate-Reducing Bacteria: Environmental and Engineered Systems; Cambridge University Press: Cambridge, UK, 2010; p. 553.

18. Kotrová, V.; Kushkevych, I. Possible methods for evaluation of hydrogen sulfide toxicity against lactic acid bacteria. Biointerface Res. Appl. Chem. 2019, 9, 4066–4069.

19. Pitcher, M.C.; Cummings, J.H. Hydrogen sulphide: A bacterial toxin in ulcerative colitis? Gut 1996, 39, 1–4.

20. Kushkevych, I.; Leščanová, O.; Dördević, D.; Jančíková, S.; Hošek, J.; Vitěžová, M.; Buňková, L.; Drago, L. The Sulfate-Reducing Microbial Communities and Meta-Analysis of Their Occurrence during Diseases of Small–Large Intestine Axis. J. Clin. Med. 2019, 8, 1656.

21. Kushkevych, I.; Fafula, R.; Parak, T.; Bartoš, M. Activity of Na’/K’-activated Mg2+-dependent ATP hydrolase in the cell-free extracts of the sulfate-reducing bacteria Desulfovibrio piger Vib-7 and Desulfolmicribium sp. Rod-9. Acta Vet. Brno 2015, 84, 3–12.

22. Kushkevych, I.V. Activity and kinetic properties of phosphotransacetylase from intestinal sulfate-reducing bacteria. Acta Biochim. Pol. 2015, 62, 1037–1108.

23. Kushkevych, I.; Dördević, D.; Vitěžová, M.; Kollár, P. Cross-correlation analysis of the Desulfovibrio growth parameters of intestinal species isolated from people with colitis. Biologia 2018, 73, 1137–1143.

24. Kushkevych, I.; Dördević, D.; Vitěžová, M. Analysis of pH dose-dependent growth of sulfate-reducing bacteria. Open Med. 2019, 14, 66–74.

25. Tomasova, L.; Konopelski, P.; Ufnal, M. Gut bacteria and hydrogen sulfide: The new old players in circulatory system homeostasis. Molecules 2016, 21, 1558.

26. Kovác, J.; Vitěžová, M.; Kushkevych, I. Metabolic activity of sulfate-reducing bacteria from rodents with colitis. Open Med. 2018, 13, 344–349.

27. Kushkevych, I.; Vitěžová, M.; Fedrova, P.; Vochyanová, Z.; Paráková, L.; Hošek, J. Kinetic properties of growth of intestinal sulphate-reducing bacteria isolated from healthy mice and mice with ulcerative colitis. Acta Vet. Brno 2017, 86, 405–411.

28. Gibson, G.R.; Macfarlane, G.T.; Cummings, J. H. Occurrence of sulphate-reducing bacteria in human faeces and the relationship of dissimilatory sulphate reduction to methanogenesis in the large gut. J. Appl. Bacteriol. 1988, 65, 103–111.

29. Černý, M.; Vitěžová, M.; Vitěz, T.; Bartoš, M.; Kushkevych, I. Variation in the distribution of hydrogen producers from the clostridiales order in biogas reactors depending on different input substrates. Energies 2018, 11, 3270.
30. Kushkevych, I.; Vítězová, M.; Vítěz, T.; Bartoš, M. Production of biogas: Relationship between methanogenic and sulfate-reducing microorganisms. *Open Life Sci.* 2017, 12, 82–91.

31. Kushkevych, I.; Vítězová, M.; Vítěz, T.; Kováč, J.; Kaucká, P.; Jesínek, W.; Bartoš, M.; Barton, L. A new combination of substrates: Biogas production and diversity of the methanogenic microorganisms. *Open Life Sci.* 2018, 13, 119–128.

32. Peck, H.D.; Legall, J.; Vanbeemen, J. Biochemistry of dissimilatory sulfate reduction. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 1982, 298, 443–466.

33. Kushkevych, I.; Dordević, D.; Kollar, P. Analysis of physiological parameters of *Desulfovibrio* strains from individuals with colitis. *Open Life Sci.* 2018, 13, 481–488.

34. Loubinoux, J.; Valente, F.M.A.; Pereira, I.A.C. Reclassification of the only species of the genus *Desulfonomas*, *Desulfonomas pigra*, as *Desulfovibrio pigra* comb. nov. *Int. J. Syst. Evol. Microbiol.* 2002, 52, 1305–1308.

35. Postgate, J.R. *The Sulfate-Reducing Bacteria*, 2nd ed.; Cambridge University Press: Cambridge, UK, 1984; p. 208.

36. Abdulina, D.; Kováč, J.; Iutynska, G.; Kushkevych, I. ATP sulfurylase activity of sulfate-reducing bacteria from various ecotopes. *3Biotech* 2020, 10, 55.

37. Kushkevych, I.; Kollar, P.; Ferreira, A.L.; Palma, D.; Duarte, A.; Lopes, M.M.; Bartos, M.; Pauk, K.; Imramovský, A.; Jampilek, J. Antimicrobial effect of salicylamide derivatives against intestinal sulfate-reducing bacteria. *J. Appl. Biomol.* 2016, 14, 125–130.

38. Kushkevych, I.; Kos, J.; Kollar, P.; Kralova, K.; Jampilek, J. Activity of ring-substituted 8-hydroxyquinoline-2-carboxanilides against intestinal sulfate-reducing bacteria *Desulfovibrio pigra*. *Med. Chem. Res.* 2018, 27, 278–284.

39. Dordević, D.; Jančíková, S.; Vítězová, M.; Kushkevych, I. Hydrogen sulfide toxicity in the gut environment: Meta-analysis of sulfate-reducing and lactic acid bacteria in inflammatory processes. *J. Adv. Res.* 2020, 25, 1–15.

40. Kushkevych, I.; Dordević, D.; Vítězová, M. Possible synergy effect of hydrogen sulfide and acetate produced by sulfate-reducing bacteria on inflammatory bowel disease development. *J. Adv. Res.* 2020, 25, 1–8.

41. Moore, W.E.; Johnson, J.L.; Holdeman, L.V. Emendation of *Bacteroidaceae* and *Butyrivibrio* and descriptions of *Desulphonomas* gen. nov. and ten new species of the genera *Desulphonomas*, *Butyrivibrio*, *Eubacterium*, *Clostridium* and *Ruminococcus*. *Int. J. Syst. Bact.* 1976, 26, 238–252.

42. Brenner, D.J.; Krieg, N.R.; Staley, J.T.; Garrity, G.M. Volume Two: The Proteobacteria, Part C: The Alpha-, Beta-, Delta-, and Epsilonproteobacteria. In *Bergey’s Manual of Systematic Bacteriology* 2nd ed.; Printed in the United States of America Springer, Boston, MA, USA, 2005; p. 1388.

43. Kováč, J.; Kushkevych, I. New modification of cultivation medium for isolation and growth of intestinal sulfate-reducing bacteria. In Proceedings of the International PhD Students Conference Mendel Net, Brno, Czech Republic, 6–7 November 2019; pp. 702–707.

44. Weisburg, W.G.; Barns, S.M.; Pelletier, D.A.; Lane, D.J. 16S ribosomal DNA amplification for phylogenetic study. *J. Bacteriol.* 1991, 173, 697–703.

45. Persing, D.H. *Molecular Microbiology: Diagnostic Principles and Practice*, 2nd ed.; ASM Press: Washington, DC, USA, 2011; p. 960.

46. Komlert, A.; Wikstrom, P.; Hallberg, K.B. A fast and simple turbidimetric method for the determination of sulfate in sulfate-reducing bacterial cultures. *J. Microbiol. Methods* 2000, 41, 179–184.

47. Sugiyama, M. Reagent Composition for Measuring Hydrogen Sulfide and Method for Measuring Hydrogen. U.S. Patent 6,340,596, 22 January 2002.

48. Bailey, N.T.J. *Statistical Methods in Biology*; Cambridge University Press: Cambridge, UK, 1995.

49. Florin, T.H.; Neale, G.; Goretski, S. Sulfate in food and beverages. *J. Food Compos. Anal.* 1993, 6, 140–151.

50. Kushkevych, I.; Kováč, J.; Vítězová, M.; Vítěz, T.; Bartoš, M. The diversity of sulfate-reducing bacteria in the seven bioreactors. *Arch. Microbiol.* 2018, 200, 945–950.

51. Kushkevych, I.; Cejnar, J.; Treml, J.; Dordević, D.; Kollar, P.; Vítězová, M. Recent Advances in Metabolic Pathways of Sulfate Reduction in Intestinal Bacteria. *Cells* 2020, 9, 698.

52. Beauchamp, R.O.; Bus, J.S.; Popp, J.A.; Boreiko, C.J.; Andjelkovich, D.A.; Leber, P. A critical review of the literature on hydrogen sulfide toxicity. *CRC Crit. Rev. Toxicol.* 1984, 13, 25–97.
53. Blachier, F.; Davila, A.M.; Mimoun, S. Luminal sulfide and large intestine mucosa: Friend or foe? *Amino Acids* 2010, 39, 335–347.

54. Attene-Ramos, M.S.; Wagner, E.D.; Plewa, M.J.; Gaskins, H.R. Evidence that hydrogen sulfide is a genotoxic agent. *Mol. Cancer Res.* 2006, 4, 9–14.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).